Celldex Therapeutics, Inc. (CLDX)

Over the past six months, Celldex Therapeutics' stock price has been influenced by several events. The company reported a Q1 loss and missed revenue estimates. Celldex announced it would present Phase 2 study data of Barzolvolimab in Chronic Spontaneous Urticaria (CSU) at the EAACI Congress 2025 and reported promising Phase 2 results for Barzolvolimab in CSU, demonstrating sustained clinical benefits seven months post-treatment and a 77% angioedema-free rate at Week 52. Celldex was scheduled to present at the Morgan Stanley 23rd Annual Global Healthcare Conference and presented data at the EADV Congress 2025, showing that Barzolvolimab improves CSU independently of baseline Immunoglobulin E levels in a Phase 2 study. Mizuho initiated coverage of Celldex Therapeutics with an "Outperform" recommendation, while Barclays initiated coverage with an "Underweight" recommendation, leading to a stock price dip. Analysts issued a consensus rating of "Moderate Buy" for the stock, and Weiss Ratings reaffirmed a "Sell" rating.

The demand for Celldex Therapeutics' products and services is not typically subject to seasonal fluctuations. Demand is primarily driven by medical need, disease prevalence, clinical trial outcomes, and regulatory approvals.

Celldex Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic antibodies for severe inflammatory, allergic, autoimmune, and other diseases. The company operates within the Healthcare sector and Biotechnology industry, advancing mast cell biology. Its primary drug candidates include Barzolvolimab (CDX-0159) and CDX-622. Barzolvolimab is in Phase 2 and Phase 3 clinical studies for conditions like chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis.

Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey, United States. The company's stock is traded on the NASDAQ exchange, as well as on several German stock exchanges (Berlin, Munich, Stuttgart, Frankfurt, Dusseldorf) and the Berne Stock Exchange in Switzerland.

Celldex Therapeutics' brand reputation has been influenced by its clinical trial progress and analyst coverage. Positive Phase 2 results for Barzolvolimab in chronic spontaneous urticaria have contributed positively to its scientific and clinical reputation. Analyst ratings have been mixed, with a consensus of "Moderate Buy" but also "Sell" ratings and an "Underweight" initiation from Barclays, impacting investor perception.

Celldex Therapeutics, Inc. has a significant institutional ownership presence. Major institutional owners include Kynam Capital Management (9.19%), Wellington Management Group Llp (7.88%), Price T Rowe Associates (5.75%), Commodore Capital (5.20%), and Bellevue Group (4.98%).